CN109758483B - 小鼠慢性萎缩性胃炎模型的制备方法 - Google Patents
小鼠慢性萎缩性胃炎模型的制备方法 Download PDFInfo
- Publication number
- CN109758483B CN109758483B CN201910245354.5A CN201910245354A CN109758483B CN 109758483 B CN109758483 B CN 109758483B CN 201910245354 A CN201910245354 A CN 201910245354A CN 109758483 B CN109758483 B CN 109758483B
- Authority
- CN
- China
- Prior art keywords
- mice
- mouse
- atrophic gastritis
- chronic atrophic
- helicobacter pylori
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000016644 chronic atrophic gastritis Diseases 0.000 title claims abstract description 42
- 238000002360 preparation method Methods 0.000 title claims abstract description 8
- 241000699670 Mus sp. Species 0.000 claims abstract description 33
- 241000590002 Helicobacter pylori Species 0.000 claims abstract description 29
- 241000699666 Mus <mouse, genus> Species 0.000 claims abstract description 29
- 229940037467 helicobacter pylori Drugs 0.000 claims abstract description 29
- UKIDUMMXBQMTKO-UHFFFAOYSA-N 1-methyl-1-nitro-2-nitrosoguanidine Chemical compound [O-][N+](=O)N(C)C(=N)NN=O UKIDUMMXBQMTKO-UHFFFAOYSA-N 0.000 claims abstract description 22
- 238000000034 method Methods 0.000 claims abstract description 17
- 210000001156 gastric mucosa Anatomy 0.000 claims abstract description 15
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims abstract description 14
- 235000011114 ammonium hydroxide Nutrition 0.000 claims abstract description 12
- 101100476480 Mus musculus S100a8 gene Proteins 0.000 claims abstract description 8
- 239000003651 drinking water Substances 0.000 claims abstract description 5
- 235000020188 drinking water Nutrition 0.000 claims abstract description 5
- 238000003304 gavage Methods 0.000 claims abstract description 5
- 206010061218 Inflammation Diseases 0.000 claims abstract description 4
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 4
- 230000004054 inflammatory process Effects 0.000 claims abstract description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 4
- 208000015181 infectious disease Diseases 0.000 claims description 11
- 238000000465 moulding Methods 0.000 claims description 10
- 230000002496 gastric effect Effects 0.000 claims description 5
- 208000035143 Bacterial infection Diseases 0.000 claims description 3
- 208000018380 Chemical injury Diseases 0.000 claims description 3
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 3
- 230000037396 body weight Effects 0.000 claims description 3
- 230000010412 perfusion Effects 0.000 claims description 3
- 239000007621 bhi medium Substances 0.000 claims description 2
- 230000003203 everyday effect Effects 0.000 claims description 2
- 238000010172 mouse model Methods 0.000 claims 1
- 238000010171 animal model Methods 0.000 abstract description 6
- 201000010099 disease Diseases 0.000 abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 5
- 230000036285 pathological change Effects 0.000 abstract description 5
- 231100000915 pathological change Toxicity 0.000 abstract description 5
- 230000001575 pathological effect Effects 0.000 abstract description 5
- 206010019375 Helicobacter infections Diseases 0.000 abstract description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 abstract description 2
- 206010017758 gastric cancer Diseases 0.000 abstract description 2
- 201000011549 stomach cancer Diseases 0.000 abstract description 2
- 238000010562 histological examination Methods 0.000 abstract 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 208000007882 Gastritis Diseases 0.000 description 2
- 241000699684 Meriones unguiculatus Species 0.000 description 2
- ZRKWMRDKSOPRRS-UHFFFAOYSA-N N-Methyl-N-nitrosourea Chemical compound O=NN(C)C(N)=O ZRKWMRDKSOPRRS-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 238000003794 Gram staining Methods 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 206010054949 Metaplasia Diseases 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 108010046334 Urease Proteins 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 229960004025 sodium salicylate Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/02—Breeding vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/02—Ammonia; Compounds thereof
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Environmental Sciences (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Inorganic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
小鼠慢性萎缩性胃炎模型的制备方法,按小鼠体重灌N‑甲基‑N‑硝基‑亚硝基胍,饲养饮水使用低含量的氨水;用N‑甲基‑N‑硝基‑亚硝基胍干预完后灌CagA和VagA为阳性的幽门螺杆菌;灌胃前小鼠禁食,灌胃后禁食禁水;抽取雌雄小鼠,进行胃黏膜病理组织学检查,并从胃粘膜分离培养幽门螺杆菌,确认幽门螺杆菌定植和炎症形成。该方法用小鼠构建慢性萎缩性胃炎,操作简单、成本低廉、周期短、成功率高、病理改变稳定,可重复性强,具备突出的实质性特点,可为研究幽门螺杆菌感染导致的慢性萎缩性胃炎、胃癌等疾病提供良好的动物模型。
Description
技术领域
本发明属于医药领域,具体涉及小鼠慢性萎缩性胃炎模型的制备方法。
背景技术
慢性萎缩性胃炎(chronic atrophic gastritis,CAG)作为胃癌前期疾病的一种,其发病缓慢,病势缠绵,迁延难愈,治疗棘手,控制不好可向肠上皮化生或不典型增生发展,最后形成胃癌。关于CAG研究与治疗都备受瞩目,CAG动物模型的造模,是该疾病基础与临床研究的关键素材,良好的动物模型为将为该疾病的防治研究提供直接的体内证据。构建慢性萎缩性胃炎动物模型方法主要有化学致癌法和幽门螺杆菌感染法等,但截至目前,模型的构建还不理想,还有有很多地方值得探索,比如实验动物的选择、药物的组合及剂量的大小、造模时间的长短、操作的简便性等。N-甲基-N-硝基-亚硝基胍、氨水、脱氧胆酸钠、水杨酸钠等均是目前常用的化学方法造模材料,基本都是选用大鼠或蒙古沙鼠造模,很少有用小鼠构建慢性萎缩性胃炎造模,原因可能是小鼠不好控制干预的剂量,并且容易发生其它的并发症或毒副反应;幽门螺杆菌是胃炎、胃溃疡的主要病因,是构建CAG动物的唯一病原菌,其构建的动物模型更接近人类因感染发生的CAG,更有利于研究CAG的发病机制,但是幽门螺杆菌在大鼠和蒙古沙鼠比较容易定植,发病率比较高,而在小鼠体内很难定植,临床分离的菌株要经过适应性驯化才能定植,并且定植的周期比较短,一般感染后第1个月达到最大定植量,第2、3个月定植量会下降,不能持续维持比较高的感染量;中山医科大学附属第一医院曾志荣用幽门螺杆菌悉尼株(SS1)感染C57BL/6小鼠及BALB/c小鼠,虽然该菌株在体内长时间维持较高的定植量,但是该菌株是CagA阴性的菌株,以致末次接种后24周也尚未有慢性萎缩性胃炎出现;复旦大学附属中山医院王剑等用“幽门螺杆菌+N-甲基-N-亚硝基脲(MNU)”联合造模,36周小鼠出现慢性萎缩性胃炎是23.1%,这需要很长的周期且成功率低;我们前期预实验选用小鼠,采用“幽门螺杆菌组+N-甲基-N-硝基-亚硝基胍组”方法造模,在末次感染后第4个月小鼠尚未出现慢性萎缩性胃炎。可见,要在较短的周期内用幽门螺杆菌感染小鼠制备慢性萎缩性胃炎非常困难。因此,本发明采用多因素组合的方法,用“幽门螺杆菌+N-甲基-N-硝基-亚硝基胍+氨水”三因素联合造模方法制备小鼠慢性萎缩性胃炎模型,该方法是先用N-甲基-N-硝基-亚硝基胍损伤胃粘膜和免疫抑制,再用含量较低的氨水中和胃酸,使CagA和VagA阳性的幽门螺杆菌能够保持较高的定植剂量。本发明的目的是提供操作简单、成本低廉、周期短、成功率高、病理改变稳定的慢性萎缩性胃炎造模方法,为防治CAG奠定坚实的实验基础。
发明内容
解决的技术问题:本发明提供一种小鼠慢性萎缩性胃炎模型的制备方法,降低实验操作难度,节约实验成本,缩短造模周期,有稳定的病理变化,提高造模的成功率。
技术方案:小鼠慢性萎缩性胃炎模型的制备方法,步骤为:a.免疫干预和化学损伤:按小鼠体重5mL/kg灌100~120μg/mL浓度的N-甲基-N-硝基-亚硝基胍,每天1次,连续干预7次;饲养饮水使用0.02~0.04wt.%氨水;b.细菌感染:用N-甲基-N-硝基-亚硝基胍灌胃完成后,用BHI培养基调配CagA和VagA为阳性的幽门螺杆菌浓度为1×109CFU/mL,用该菌灌胃感染小鼠;灌胃前小鼠禁食12小时,实验组每只小鼠灌1~10×108CFU幽门螺杆菌,灌胃后禁食禁水2小时,隔天1次,连续灌5次;c.确定造模成功:分别在第1、2、3、4个月,抽取雌雄各5只小鼠,进行胃黏膜病理组织学检查,并从胃粘膜分离培养幽门螺杆菌,确认幽门螺杆菌定植和炎症形成。
优选的,上述的动物是小鼠。
优选的,上述每只小鼠灌CagA和VagA为阳性的幽门螺杆菌浓度为5×108CFU。
优选的,上述按小鼠体重5mL/kg灌120μg/mL的N-甲基-N-硝基-亚硝基胍。
优选的,上述饲养饮水使用0.02wt.%氨水。
有益效果:1.本发明成功构建了小鼠CAG模型。2.本发明构建的小鼠CAG模型在3个月内成功率为90%,构建方法操作简单,实验成本低,周期短,病理变化稳定,是较好的CAG模型构建方法。
附图说明
图1为正常小鼠胃粘膜HE染色病理图片。
图2为实验组小鼠感染后1个月胃粘膜HE染色病理图片。
图3为实验组小鼠感染后3个月胃粘膜HE染色病理图片。
图4为实验组小鼠感染后4个月胃粘膜HE染色病理图片。
图5为实验组小鼠感染后1、2、3、4个月胃粘膜幽门螺杆菌定植量。
具体实施方式
实施例1
1.动物分组:随机选280只6周龄的昆明小鼠,分为PBS对照组、幽门螺杆菌组、N-甲基-N-硝基-亚硝基胍组、氨水组、“幽门螺杆菌组+N-甲基-N-硝基-亚硝基胍”两因素联合造模组、“幽门螺杆菌组+基-N-硝基-亚硝基胍组+氨水”三因素联合造模组,雌雄各半。
2.免疫干预和化学损伤:实验组按小鼠体重5mL/kg灌120μg/mL浓度的N-甲基-N-硝基-亚硝基胍,每天1次,连续干预7次,饲养饮水使用0.02wt.%氨水。对照组:不用任何干预,正常饲养。
3.细菌感染:采用临床分离的幽门螺杆菌菌株,经革兰氏染色、尿素酶试验、氧化酶试验、过氧化氢酶试验及16S鉴定为幽门螺杆菌,菌株CagA和VagA为阳性,增殖培养该幽门螺杆菌3天,用BHI培养基调配浓度为1×109CFU/mL;用N-甲基-N-硝基-亚硝基胍干预完后,再用幽门螺杆菌灌胃;灌胃前小鼠禁食12小时,实验组每只小鼠灌5×108CFU幽门螺杆菌,灌胃后禁食禁水2小时,隔天1次,连续灌5次。对照组每只灌0.5mLBHI培养基,同样灌5次。
4.确定造模成功:分别在第1、2、3、4个月,从实验组和对照组中随机抽取雌雄各5只小鼠,进行胃黏膜病理组织学检查,并从胃粘膜分离培养幽门螺杆菌,确认幽门螺杆菌定植和炎症形成。
5.实验结果:三因素联合造模组小鼠感染后第一个月,全部小鼠均发生急性胃炎,尚未发现有慢性萎缩性胃炎小鼠,如图2;第二个月与第一个月对比没有明显差异;第三个月90%(9/10)出现轻度慢性萎缩性胃炎,如图3,第4个月小鼠由轻度慢性萎缩性胃炎变为中度慢性萎缩性胃炎,如图4。实验组小鼠感染后1-4个月每克胃粘膜均有1×104-5CFU定植,组间无显著性差异,如图5和表1,幽门螺杆菌验证如表2。PBS对照组、幽门螺杆菌组、N-甲基-N-硝基-亚硝基胍组、氨水组及两因素联合造模组小鼠未见有慢性萎缩性胃炎。幽门螺杆菌组和两因素联合造模组虽然有幽门螺杆菌定植,但是定植的数量比较低,这可能是不出现慢性萎缩性胃炎的原因。
6.实验结论:“幽门螺杆菌+N-甲基-N-硝基-亚硝基胍+氨水”三因素联合造模的方法构建小鼠慢性萎缩性胃炎3个月的成功率是90%,4个月病理变化更明显,是比较理想的小鼠慢性萎缩性胃炎制备方法。
表1慢性萎缩性胃炎造模结果
表2造模小鼠分离培养物验证
实施例2
采用上述实施例1的方法,幽门螺杆菌按每只小鼠灌1×108CFU,N-甲基-N-硝基-亚硝基胍按小鼠体重5mL/kg灌100μg/mL浓度的灌胃,每天1次,连续干预7次,饲养饮水使用0.04wt.%氨水,实验结果见表2。
表2慢性萎缩性胃炎造模结果
实施例3
采用上述实施例1的方法,幽门螺杆菌按每只小鼠灌1×109CFU,N-甲基-N-硝基-亚硝基胍按小鼠体重5mL/kg灌110μg/mL浓度的灌胃,每天1次,连续干预7次,饲养饮水使用0.03wt.%氨水,实验结果见表3。
表3慢性萎缩性胃炎造模结果
Claims (4)
1.小鼠慢性萎缩性胃炎模型的制备方法,其特征在于步骤为:
a. 免疫干预和化学损伤:按小鼠体重5 mL/kg灌100~120μg/mL浓度的N-甲基-N-硝基-亚硝基胍,每天1次,连续干预7次;饲养饮水使用0.02~0.04wt.%氨水;
b. 细菌感染:用N-甲基-N-硝基-亚硝基胍灌胃完成后,用BHI培养基调配CagA和VagA为阳性的幽门螺杆菌浓度为1×109CFU/mL,用该菌灌胃感染小鼠;灌胃前小鼠禁食12小时,实验组每只小鼠灌1~10×108CFU幽门螺杆菌,灌胃后禁食禁水2小时,隔天1次,连续灌5次;
c. 确定造模成功:分别在第1、2、3、4个月,抽取雌雄各5只小鼠,进行胃黏膜病理组织学检查,并从胃粘膜分离培养幽门螺杆菌,确认幽门螺杆菌定植和炎症形成。
2.根据权利要求1所述小鼠慢性萎缩性胃炎模型的制备方法,其特征在于所述每只小鼠灌CagA和VagA为阳性的幽门螺杆菌浓度为5×108CFU。
3.根据权利要求1所述小鼠慢性萎缩性胃炎模型的制备方法,其特征在于按小鼠体重5mL/kg灌120μg/mL的N-甲基-N-硝基-亚硝基胍。
4.根据权利要求1所述小鼠慢性萎缩性胃炎模型的制备方法,其特征在于所述饲养饮水使用0.02wt.%氨水。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810686439.2A CN109010379A (zh) | 2018-06-28 | 2018-06-28 | 慢性萎缩性胃炎动物模型的制备方法 |
CN2018106864392 | 2018-06-28 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109758483A CN109758483A (zh) | 2019-05-17 |
CN109758483B true CN109758483B (zh) | 2020-03-17 |
Family
ID=65520647
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810686439.2A Pending CN109010379A (zh) | 2018-06-28 | 2018-06-28 | 慢性萎缩性胃炎动物模型的制备方法 |
CN201910245354.5A Active CN109758483B (zh) | 2018-06-28 | 2019-03-28 | 小鼠慢性萎缩性胃炎模型的制备方法 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810686439.2A Pending CN109010379A (zh) | 2018-06-28 | 2018-06-28 | 慢性萎缩性胃炎动物模型的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (2) | CN109010379A (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113940309B (zh) * | 2021-09-09 | 2022-10-18 | 重庆医科大学附属儿童医院 | 一种慢性萎缩性胃炎病变的模拟方法及小鼠造模鉴定方法 |
CN113940310A (zh) * | 2021-10-26 | 2022-01-18 | 浙江大学 | 一种小鼠胃癌模型的建立方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102648701A (zh) * | 2011-02-25 | 2012-08-29 | 潘华峰 | 一种脾虚证慢性萎缩性胃炎胃癌前病变动物模型的建立方法 |
CN103446576B (zh) * | 2013-09-12 | 2014-10-08 | 光明乳业股份有限公司 | 一种幽门螺杆菌感染动物模型的建立方法 |
CN105651804B (zh) * | 2016-03-11 | 2017-05-17 | 山西大学 | 一种慢性萎缩性胃炎大鼠模型的评价方法 |
-
2018
- 2018-06-28 CN CN201810686439.2A patent/CN109010379A/zh active Pending
-
2019
- 2019-03-28 CN CN201910245354.5A patent/CN109758483B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN109758483A (zh) | 2019-05-17 |
CN109010379A (zh) | 2018-12-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Timbermont et al. | Origin of Clostridium perfringens isolates determines the ability to induce necrotic enteritis in broilers | |
CN109758483B (zh) | 小鼠慢性萎缩性胃炎模型的制备方法 | |
JPH0335796A (ja) | 環状デプシペプチド物質およびその製造法、ならびにそれを含有する駆虫剤 | |
JP2010532347A5 (zh) | ||
WO2018231992A2 (en) | Methods of using lactobacillus plantarum strains for protecting animals from pathogenic bacterial infection | |
CN111011856A (zh) | 用于缓解胃病的组合物、其制备方法及用于缓解胃病的食品 | |
CN108836956B (zh) | 甘草查耳酮a在制备治疗鸡坏死性肠炎药物中的用途 | |
ITMO20130241A1 (it) | Uso di indolo-3-aldeide per il trattamento di patologie disreattive immunitarie | |
CN108434127B (zh) | 一种杨梅醇和/或杨梅酮在制备具有预防和/或治疗炎症性肠病的药物中的应用 | |
CN108207791B (zh) | 新生仔猪肠道正常健康功能菌群早期建立方法 | |
KR20180104834A (ko) | 아족시메탄 없이 유도된 대장암 동물모델의 제조방법 | |
Ehlers et al. | In search of an animal model for experimental Campylobacter pylori infection: administration of Campylobacter pylori to rodents | |
EP2943220A2 (en) | Vaccine | |
CN101780266A (zh) | 防治畜禽呼吸道疾病的复方制剂 | |
CN103918899A (zh) | 一种黄芪多糖的用途 | |
DeVolt et al. | Preliminary report on the preventive action of vioform against infectious enterohepatitis (blackhead) of turkeys | |
RU2470663C1 (ru) | Вакцина против сальмонеллеза свиней, способ изготовления, способ профилактики сальмонеллеза свиней | |
Vera-Cabrera et al. | Experimental mycetoma by Nocardia brasiliensis in rats | |
Kessler et al. | Treatment of tetanus in the rhesus monkey (Macaca mulatta) | |
CN105764520B (zh) | 甲壳类的传染病的抑制方法 | |
CN104257721B (zh) | 一种防治水产动物链球菌病的中药组合物 | |
KR20150019934A (ko) | 락토코커스 락티스를 이용한 어류의 면역 증진 방법 | |
DE102017004217A1 (de) | Verwendung der Hefe Kazachstania sloofiae zur Verbesserung der Darmgesundheit von Schweinen | |
JP3543739B2 (ja) | 魚病用ワクチン | |
CN116286390A (zh) | 一种驯化总状毛霉及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |